Literature DB >> 22481389

Companies hope for rare win with cancer stem cell therapies.

Anna Azvolinsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22481389     DOI： 10.1038/nm0412-474a

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  3 in total

1.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Authors:  Sarah J Conley; Elizabeth Gheordunescu; Pramod Kakarala; Bryan Newman; Hasan Korkaya; Amber N Heath; Shawn G Clouthier; Max S Wicha
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

2.  Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

Authors:  Marcus Fischer; Wan-Ching Yen; Ann M Kapoun; Min Wang; Gilbert O'Young; John Lewicki; Austin Gurney; Timothy Hoey
Journal:  Cancer Res       Date:  2010-12-30       Impact factor: 12.701

3.  DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

Authors:  Timothy Hoey; Wan-Ching Yen; Fumiko Axelrod; Jesspreet Basi; Lucas Donigian; Scott Dylla; Maureen Fitch-Bruhns; Sasha Lazetic; In-Kyung Park; Aaron Sato; Sanjeev Satyal; Xinhao Wang; Michael F Clarke; John Lewicki; Austin Gurney
Journal:  Cell Stem Cell       Date:  2009-08-07       Impact factor: 24.633
  3 in total
  1 in total

1.  HepG2 cells acquire stem cell-like characteristics after immune cell stimulation.

Authors:  Hang Wang; Miqing Yang; Ling Lin; Hongzhen Ren; Chaotong Lin; Suling Lin; Guoying Shen; Binfeng Ji; Chun Meng
Journal:  Cell Oncol (Dordr)       Date:  2015-12-09       Impact factor: 6.730
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.